THRIVE Drug Patent Profile
✉ Email this page to a colleague
When do Thrive patents expire, and when can generic versions of Thrive launch?
Thrive is a drug marketed by Glaxosmithkline Cons and is included in two NDAs.
The generic ingredient in THRIVE is nicotine polacrilex. There is one drug master file entry for this compound. Sixty suppliers are listed for this compound. Additional details are available on the nicotine polacrilex profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Thrive
A generic version of THRIVE was approved as nicotine polacrilex by P AND L on March 15th, 1999.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for THRIVE?
- What are the global sales for THRIVE?
- What is Average Wholesale Price for THRIVE?
Summary for THRIVE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Clinical Trials: | 56 |
| DailyMed Link: | THRIVE at DailyMed |
Recent Clinical Trials for THRIVE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Florida | PHASE1 |
| Assistance Publique - Hôpitaux de Paris | PHASE2 |
| Chang Gung Memorial Hospital | NA |
US Patents and Regulatory Information for THRIVE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline Cons | THRIVE | nicotine polacrilex | GUM, CHEWING;BUCCAL | 077658-001 | Jun 19, 2007 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Glaxosmithkline Cons | THRIVE | nicotine polacrilex | GUM, CHEWING;BUCCAL | 077656-001 | Jun 19, 2007 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
